Effect of Semaglutide on Embryo Quality in Overweight and Obese Patients Undergoing In Vitro Fertilization.
Key facts
- Where
- Barcelona, Reus, Sabadell, Sant Cugat del Vallès, and Tarragona, SpainSee the 5 sites
- Phase
- Phase 4
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 38 years old?
Where in Spain
- Departamento de Ginecología Obstetricia y Reproducción. Hospital Universitari DexeusBarcelona, SpainTaking people
- Dexeus Mujer ReusReus, SpainNot yet recruiting
- Dexeus Mujer SabadellSabadell, SpainNot yet recruiting
- Dexeus Mujer Sant CugatSant Cugat del Vallès, SpainNot yet recruiting
- Dexeus Mujer TarragonaTarragona, SpainNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Fundacion Dexeus
- Trial code
- NCT07242534EU 2025-522525-34-00
- Record updated
- 21 January 2026
- Original description
This is a randomized, controlled clinical trial with a two-sided superiority hypothesis. The study evaluates whether a 12-week pre-treatment with semaglutide prior to ovarian stimulation improves the number of good-quality blastocysts in overweight and obese women undergoing in vitro fertilization (IVF), compared to no pre-treatment.Read full original descriptionShow less
Effect of Semaglutide on Embryo Quality in Overweight and Obese Patients Undergoing In Vitro Fertilization. A Randomized Controlled Trial
This is a randomized, controlled clinical trial with a two-sided superiority hypothesis. The study evaluates whether a 12-week pre-treatment with semaglutide prior to ovarian stimulation improves the number of good-quality blastocysts in overweight and obese women undergoing in vitro fertilization (IVF), compared to no pre-treatment.
Inclusion: ≤ 38 years; AMH >= 1 ng/mL or AFC >= 6; Body mass index (BMI) between 27 kg/m2 and 40 kg/m2; Scheduled for IVF with freeze-all strategy.
Exclusion: Prior use of GLP-1 Ras within the past year; Use of medications affecting metabolism or inflammation; Type 2 diabetes mellitus; Uncontrolled thyroid disorders; Patients with chronic inflammatory diseases; Family history of hereditary or chromosomal diseases; Severe male factor (sperm concentration <5M/mL); Contraindications to IVF or semaglutide treatment; Use of glucocorticoids or immunosuppressants; PGT-A.